

OMICS GROUP



OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over **400** leading-edge peer reviewed Open Access Journals and organizes over **300** International Conferences annually all over the world. OMICS Publishing Group journals have over **3 million** readers and the fame and success of the same can be attributed to the strong editorial board which contains over **30000** eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than **1000** International Societies to make healthcare information Open Access.

OMICS Journals are welcoming Submissions

OMICS Group welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS Group follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website:

<http://omicsonline.org/Submitmanuscript.php>



Francisco López-Muñoz, MD PhD

Co-Editor-in-Chief

Clinical & Experimental Pharmacology

Francisco López-Muñoz's Biography

- Francisco López-Muñoz studied Medicine at Complutense University (Madrid).
- He received his PhD Degree in Medicine at Complutense University in 1993, with a Thesis on postnatal development of the rat pineal gland after chemical denervation, that won the Doctorate Extraordinary Award.
- During his pre- and post-doctoral training, he worked in neurohistology at the Department of Cellular Biology of the Complutense University.

Francisco López-Muñoz's Biography

- He is specialist in Pharmaceutical Medicine. Between 1992 and 2009, he worked in the pharmaceutical industry (Juste, S.A.Q.F.), as Medical Director.
- After 1996 he is honorary research Professor at the Pharmacology Department of the University of Alcalá, working primarily in the field of neuropsychopharmacology.
- Currently, he is Professor of Pharmacology, Director of International Doctorate School, and Sub-Director of Chair of Genomic Medicine at Camilo José Cela University (Madrid), and research fellow at “Hospital 12 de Octubre” Research Institute (Madrid)

Research Interest

- Postnatal development of mammals pineal gland chemical sympathectomy
- The biological bases of drug abuse and dual diagnosis,
- Psychotropic drugs interactions
- The neurobiology of aggressivity
- The bibliometric techniques applied to mental health-related disciplines and neuropsychopharmacology
- The combination therapies with antidepressant drugs in resistant depression and with antipsychotics drugs in patients with refractory schizophrenia
- The history of the psychopharmacology and neuroscience

Awards

- Doctorate Extraordinary Award at Complutense University (1994).
- Atlas Award on Neurosciences. Accessit to work title "Brain Evolution and Genomics: Freedom and destiny" (2014).
- Research Award at Camilo José Cela University (2014).

Conferences participated

- He has given 28 conferences and 138 communications in scientific meetings, and is member of many scientific societies (including *Collegium Internationale Neuro-Psychopharmacologicum*) and editorial boards, including *European Journal of Pharmacology* and *Frontiers in Psychopharmacology*.
- Dr. López-Muñoz has participated, as visiting Professor and Director, in postgraduate and doctorate courses from different Spanish academic centres.

Books and Paper's Published

- Dr. López-Muñoz is editor/author of 20 books, highlighting its *History of Psychopharmacology* (Editorial Médica Panamericana, 3 volumes, Madrid, 2007; and NPP Books, 4 volumes, Arlington, USA, 2014), and *Neurobiology of Depression* (CRC Press Taylor & Francis Group, Boca raton, USA, 2012), and 185 chapters of books related to the psychopharmacology and other fields of pharmacology and neuroscience.
- He has published 118 papers on indexed journals with impact factor and 190 in Spanish and Latin American journals.

Most recent and relevant Publications (I)

- López-Muñoz F, Alamo C, Rubio G, García-García P, Pardo A. Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. *Pharmacopsychiatry* 2007; 40: 14-19.
- Zimmers TA, Sheldon J, Lubarsky DA, López-Muñoz F, Waterman L, Weisman R, Koniaris LG. Lethal Injection for Execution: Chemical Asphyxiation?. *PLoS Medicine* 2007; 4: 646-653.
- López-Muñoz F, Alamo C, Dudley M, Rubio G, García-García P, Molina JD, Okasha A. Psychiatry and political-institutional abuse from the historical perspective: The ethical lessons of the Nuremberg Trial on their 60th anniversary. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2007; 31: 791-806.
- Alamo C, López-Muñoz F, Rubio G, García-García P, Pardo A. Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study. *Acta Neuropsychiatrica* 2007; 19: 291-296.
- López-Muñoz F, Alamo C, Juckel G, Assion HJ. Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part I: Monoamine oxidase inhibitors. *Journal of Clinical Psychopharmacology* 2007; 27: 555-559.
- Fangmann P, Assion HJ, Juckel G, Álamo C, López-Muñoz F. Half a century of antidepressant drugs. On the clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part II: Tricyclics and tetracyclics. *Journal of Clinical Psychopharmacology* 2008; 28: 1-4.
- López-Muñoz F, García-García P, Sáiz-Ruiz J, Mezzich JE, Rubio G, Vieta R, Álamo C. A bibliometric study of the use of the classification and diagnostic systems in psychiatry over the last 25 years. *Psychopathology* 2008; 41: 214-225.
- García-García P, López-Muñoz F, Rubio G, Martín-Agueda B, Álamo C. Phytotherapy and psychiatry: Bibliometric study of the scientific literature from the last 20 years. *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* 2008; 15: 566-576.
- López-Muñoz F, Álamo C, Quintero-Gutiérrez FJ, García-García P. A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980-2005. *European Child and Adolescent Psychiatry* 2008; 17: 381-391.
- López-Muñoz F, Álamo C, García-García P, Molina JD, Rubio G. The role of psychopharmacology in the medical abuses of the Third Reich: from euthanasia programmes to human experimentation. *Brain Research Bulletin* 2008; 77: 388-403.
- López-Muñoz F, García-García P, Álamo C. The pharmaceutical industry and the German National Socialist regime: I.G. Farben and pharmacological research. *Journal of Clinical Pharmacy and Therapeutics* 2009; 34: 67-77.
- Molina JD, Lerma-Carrillo I, Leonor M, Pascual F, Blasco-Fontecilla H, González-Parra S, López-Muñoz F, Álamo C. Combined treatment with amisulpride in patients with schizophrenia discharged from a Short-Term Hospitalization Unit: a one-year retrospective study. *Clinical Neuropharmacology* 2009; 32: 10-15.
- López-Muñoz F, Álamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. *Brain Research Bulletin* 2009; 79: 130-141.
- López-Muñoz F, Álamo C. Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today. *Current Pharmaceutical Design* 2009; 15: 1563-1586.

Most recent and relevant Publications (II)

- López-Muñoz F, Álamo C. Historical evolution of the neurotransmission concept. *Journal of Neural Transmission* 2009; 116: 515-533.
- Seguí J, López-Muñoz F, Alamo C, Camarasa X, García-García P, Pardo A. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: A 12-week prospective study. *Journal of Psychopharmacology* 2010; 24: 1201-1207.
- Rubio G, López-Muñoz F, Ferre F, Martínez-Gras I, Ponce G, Pascual JM, Jiménez-Arriero MA, Alamo C. Effects of zonisamide in the treatment of alcohol dependence. *Clinical Neuropharmacology* 2010; 33: 250-253.
- Rubio G, López-Muñoz F, Ponce G, Pascual JM, Martínez-Gras I, Ferre F, Jiménez-Arriero MA, Alamo C. Zonisamide versus diazepam in the treatment of alcohol withdrawal syndrome. *Pharmacopsychiatry* 2010; 43: 257-262.
- López-Muñoz F, Alamo C. Cartesian theories on the passions, the pineal gland and the pathogenesis of affective disorders: An early forerunner. *Psychological Medicine* 2011; 41: 449-451.
- López-Muñoz F, Alamo C, García-García P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: Half a century of anxiolytic drugs. *Journal of Anxiety Disorders* 2011; 25: 554-562.
- López-Muñoz F, Rubio G, Molina JD, Alamo C. Sadness as a passion of the soul: A psychopathological consideration of the Cartesian concept of melancholy. *Brain Research Bulletin* 2011; 85: 42-53.
- López-Muñoz F, Alamo C. Neurobiological background for the development of new drugs in schizophrenia. *Clinical Neuropharmacology* 2011; 34: 111-126.
- Molina JD, Toledo-Romero F, López-Rodríguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Muñoz F. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine. *Pharmacopsychiatry* 2011, 44: 142-147.
- López-Muñoz F, Molina JD, Rubio G, Alamo C. An historical view of the pineal gland and mental disorders. *Journal of Clinical Neuroscience* 2011; 18: 1028-1037.
- López-Muñoz F, Shen WW, Pae CU, Moreno R, Rubio G, Molina JD, Noriega C, Pérez-Nieto MA, Huelves L, Álamo C. Trends in scientific literature on atypical antipsychotics in South Korea: A bibliometric study. *Psychiatry Investigation* 2013; 10: 8-16.
- López-Muñoz F, Álamo C. Active metabolites as antidepressant drugs: The role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. *Frontiers in Psychiatry* 2013; 4: 102. doi: 10.3389/fpsy.2013.00102.
- Cacabelos R, Torrellas C, López-Muñoz F. Epigenomics of Alzheimer's disease. *Journal of Experimental and Clinical Medicine* 2014; 6: 75-82.
- Álamo C, López-Muñoz F, García-García P. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. *Expert Reviews of Neurotherapeutics* 2014; 14: 593-605.
- López-Muñoz F, Shen WW, Shinfuku N, Pae CU, Castle DL, Chung AK, Sim K, Álamo C. A bibliometric study on second-generation antipsychotic drugs in the Asia-Pacific Region. *Journal of Experimental and Clinical Medicine* 2014; 6: 111-117.

Clinical & Experimental Pharmacology related Journals

<http://omicsgroup.org/journals/clinical-pharmacology-biopharmaceutics.php>

<http://esciencecentral.org/journals/cardiovascular-pharmacology.php>



OMICS Group Open Access Membership

OMICS publishing Group Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors.

For more details and benefits, click on the link below:

<http://omicsonline.org/membership.php>

